ICBC CSOP S&P NEW CHINA SECTORS ETF (03167.HK) Drops 0.37% to HK$64.000
New time space News, according to the latest data from the HKEX, as of9:45onMay 6, the ICBC CSOP S&P NEW CHINA SECTORS ETF (03167.HK) declined0.37% to a trading price of HK$64.000. The intraday high was HK$63.860and the low was HK$63.840, with an average price of HK$63.849. The total AUM stands at approximately HK$517 million, with the latest Net Asset Value (NAV) per unit at HK$63.855, representing a premium of +0.60%.
The ICBC CSOP S&P NEW CHINA SECTORS ETF (03167.HK) tracks the S&P New China Sectors (A-Share Capped) Index, a thematic benchmark designed to capture the dividends of China’s economic transformation. Its constituents are primarily selected from "New Economy" sectors such as Consumption, Services, and Technology, with a cap on A-share weightings to balance cross-market allocation. By assembling leading high-quality Chinese enterprises listed across A-shares, H-shares, and US-listed ADRs (such as internet platforms, healthcare, and new energy stocks), the index provides global investors with an efficient tool to bypass traditional financial and energy sectors while gaining deep exposure to the long-term growth drivers of the Chinese economy.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment
- NEW CENTURY GP(00234.HK): Indirect Non-wholly-owned Subsidiary Grants HK$8.7 Million Mortgage Loan to Wong Kwok Keung and Jiayuan Holdings at 12% Per Annum
- TAT HONG EQUIP(02153.HK): 10th Digital Securities Commercial Paper Issuance; Annual Interest Rate 4.40%, Planned Raising of SGD30 Million–35 Million